Managing resistance to anti-HIV drugs: An important consideration for effective disease management

被引：0

作者：

Vandamme A.-M. ^{[1
]}

Van Laethem K. ^{[1
]}

De Clercq E. ^{[1
]}

机构：

[1] Rega Institute for Medical Research, University Hospitals, Katholieke Universiteit Leuven

来源：

Drugs | 1999年 / 57卷 / 3期

关键词：

Human Immunodeficiency Virus; Viral Load; Adis International Limited; Didanosine; Adefovir Dipivoxil;

D O I：

10.2165/00003495-199957030-00006

中图分类号：

学科分类号：

摘要：

Current recommendations for the treatment of HIV-infected patients advise highly active antiretroviral therapy (HAART) consisting of combinations of 3 or more drugs to provide long-term clinical benefit. This is because only a complete suppression of virus replication will be able to prevent virus drug resistance, the main cause of drug failure. Virus drug resistance may remain a cause of concern in patients who have already received suboptimal mono- or bitherapy, or for patients who do not experience complete shut-down of virus replication under HAART. For these patients, replacement of one combination therapy regimen by another at drug failure, taking into account the existing resistance profile, will be needed. The development of new drugs will remain necessary for those patients who have failed to respond to all currently available drugs, as will be the institution of more effective and less toxic HAART regimens.

引用

页码：337 / 361

页数：24

共 50 条

[11] Anti-HIV drugs and the mitochondria
Pinti, Marcello
Salomoni, Paolo
Andrea, Cossarizza
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2006, 1757 (5-6): : 700 - 707
[12] Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs
Gunaseelan, Simi
Gunaseelan, Krishnan
Deshmukh, Manjeet
Zhang, Xiaoping
Sinko, Patrick J.
ADVANCED DRUG DELIVERY REVIEWS, 2010, 62 (4-5) : 518 - 531
[13] Assault on resistance: The use of computational chemistry in the development of anti-HIV drugs
Smith, Marilyn B. Kroeger
Smith, Richard H., Jr.
Jorgensen, William L.
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (15) : 1843 - 1856
[14] Timing the Emergence of Resistance to Anti-HIV Drugs with Large Genetic Barriers
Arora, Pankhuri
Dixit, Narendra M.
PLOS COMPUTATIONAL BIOLOGY, 2009, 5 (03)
[15] Synthesis routes to anti-HIV drugs
Mandala, Devender
Thompson, Warren A.
Watts, Paul
TETRAHEDRON, 2016, 72 (24) : 3389 - 3420
[16] COMPASSIONATE RELEASE OF ANTI-HIV DRUGS
MILLS, A
LANCET, 1989, 2 (8676): : 1399 - 1399
[17] New class of anti-HIV drugs
Stephenson, J
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21): : 1994 - 1994
[18] Delivery of anti-HIV drugs - Preface
Lee, YH
Sinko, PJ
ADVANCED DRUG DELIVERY REVIEWS, 1999, 39 (1-3) : 1 - 3
[19] Targeting anti-HIV drugs to the CNS
Rao, Kavitha S.
Ghorpade, Anuja
Labhasetwar, Vinod
EXPERT OPINION ON DRUG DELIVERY, 2009, 6 (08) : 771 - 784
[20] Anti-HIV drugs, profits and politics
不详
REPRODUCTIVE HEALTH MATTERS, 2001, 9 (17) : 231 - 231

← 1 2 3 4 5 →